2021 NeXT Level Biomarkers Symposium: Biomarker Discovery with ImmunoID NeXT Platform
2021 NeXT Level Biomarkers Symposium: Biomarker Discovery with Personalis NeXT Platform Erin Newburn, PhD Director, Field Applications Scientist
2021 NeXT Level Biomarkers Symposium: Biomarker Discovery with Personalis NeXT Platform Erin Newburn, PhD Director, Field Applications Scientist
2021 AACR Personalis Product Demo Advancing Biomarker Discovery: Enabling improved tumor immunogenomics through a comprehensive approach Travis Yates, PhD Field Applications Scientist This presentation will cover: Predicting patient response to immunotherapies requires a robust and comprehensive approach to tumor immunogenomics. By combining highly [...]
An Empirical Antigen Selection Method Identifies Neoantigens That Either Elicit Broad Antitumor T-cell Responses or Drive Tumor Growth. Cancer Discovery March 2021 Hubert Lam et al. View Publication View PDF
CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study. The Lancet Oncology January 2021 O'Hara, Mark H et al. View Publication
Whole-exome sequencing based immunogenomic profiling with potential clinical applicability in circulating cell-free DNA and tissue from advanced stage colorectal cancer patients. Journal for ImmunoTherapy of Cancer November 2020 Feng Z, Scheuenpflug J, Tan M et al. View Publication View PDF
A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer. Cell October 2020 Ott, Patrick A et al. View Publication
Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial. Nature Medicine September 7, 2020 Motzer, RJ, Robbins, PB, Powles, T et al. View Publication View PDF
Safety and activity of ibrutinib in combination with durvalumab in patients with relapsed or refractory follicular lymphoma or diffuse large B-cell lymphoma. American Journal of Hematology January 2020 Herrera AF, Goy A, Mehta A et al. View Publication View PDF
Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study. The Lancet Gastroenterology & Hepatology September 1, 2019 Lowery, Maeve A et al. View Publication
Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial. The Lancet Oncology December 9, 2016 Dimopoulos, Meletios A et al. View Publication